Abstract

Monocyte chemotactic protein-3 (MCP3) is recently identified and molecularly cloned C-C chemokine that is chemotactic for and activates a great variety of inflammatory cell types. MCP3 has been reported to interact with several C-C chemokine receptors, which can be simultaneously or selectively expressed on leukocyte subpopulations. In order to isolate receptor(s) for MCP3, a cDNA library was constructed using mRNA from a human NK-like cell line, YT. These cells showed high affinity binding sites for 125I-MCP3 and migrated in response to MCP3. A chemokine receptor cDNA clone, designated YT4, was sequenced and found to be identical to the known C-C CKR1 or macrophage inflammatory protein-1 alpha (MIP1 alpha)/Rantes receptor. YT4 cDNA was subcloned into a mammalian expression vector, and stable transfectants were prepared using the embryonic kidney cell line 293. The transfectants (YT4/293) showed high affinity binding for 125I-MCP3 in addition to specifically binding 125I-MIP1 alpha and 125I-Rantes. All three C-C chemokines were able to cross-compete for binding sites on YT4/293 cells and induced directional migration of YT4/293 cells in vitro, with MCP3 being the most potent chemoattractant. MCP3, MIP1 alpha, and Rantes were equally able to cross-attenuate the migratory response of YT4/293 cells to one another. In contrast, MCP1 and MIP1 beta had very limited capacity to compete for MCP3 binding on YT4/293 cells and had only a minor attenuating effect on MCP3-induced migration. Since MCP3 has been reported to use MCP1 receptor(s), our results with transfected 293 cells expressing only C-C CKR1 clearly establish that C-C CKR1 is also a functional receptor for MCP3.

Highlights

  • From the Laboratory of Molecular Immunoregulation, Biological Response Modifiers Program and the ‡Biological Carcinogenesis and Development Program, SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702, the §Department of Molecular Immunology, Smith-Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406

  • Monocyte chemotactic protein-3 (MCP3) activates a variety of inflammatory cells through a number of different binding sites for C-C chemokines expressed on these cells

  • Previous studies based on desensitization of calcium flux predicted that MCP3 would be able to interact with at least three types of receptors: 1) MCP1 receptor on monocytes and basophils [4, 6, 7], 2) selective Rantes receptor on basophils and eosinophils [6, 7], and 3) selective MIP1␣ receptor on basophils, eosinophils, and neutrophils [6]

Read more

Summary

Introduction

From the Laboratory of Molecular Immunoregulation, Biological Response Modifiers Program and the ‡Biological Carcinogenesis and Development Program, SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702, the §Department of Molecular Immunology, Smith-Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406. In order to isolate receptor(s) for MCP3, a cDNA library was constructed using mRNA from a human NK-like cell line, YT These cells showed high affinity binding sites for 125I-MCP3 and migrated in response to MCP3. A chemokine receptor cDNA clone, designated YT4, was sequenced and found to be identical to the known C-C CKR1 or macrophage inflammatory protein-1␣ (MIP1␣)/Rantes receptor. MIP1␣ and Rantes which are about 30% identical to MCP3, both activate eosinophils, in addition to monocytes (6 – 8), T lymphocytes [10], and basophils By using human embryonic kidney cell line transfected with a C-C CKR1 cDNA, we show that C-C CKR1 is a functional receptor shared by MCP3, MIP1␣, and Rantes

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call